Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood (2024) 144 (11): 1193–1205.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Blood (2024) 144 (1): 35–45.

https://doi.org/10.1182/blood.2023022658

Published: 2024

Includes: Supplemental data

Journal Articles

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Barbara De Moerloose, Nira Arad-Cohen, Daniel Cheuk, Jose Maria Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Gertjan J.L. Kaspers, Zhanna Kovalova, Birgitte Lausen, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Maria Tierens, Bernward Zeller, Jonas Abrahamsson

Blood (2023) 142 (Supplement 1): 831.

https://doi.org/10.1182/blood-2023-187251

Published: 2023

Journal Articles

Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012

Bernward Zeller, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose Maria Fernandez Navarro, Henrik Hasle, Jahnukainen Kirsi, Kristian Juul-Dam, Gertjan J.L. Kaspers, Zhanna Kovalova, Birgitte Lausen, Monica C. Munthe-Kaas, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Maria Tierens, Jonas Abrahamsson

Blood (2023) 142 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2023-184921

Published: 2023

Journal Articles

Early Peripheral Blood Blast Clearance As a Prognostic Marker for Early Treatment Response in Pediatric Acute Myeloid Leukemia

Noa E. Wijnen, Bianca de Boer, Kim Klein, Jonas Abrahamsson, Barbara De Moerloose, Bernward Zeller, Henrik Hasle, Zhanna Kovalova, Nira Arad-Cohen, Gertjan J.L. Kaspers

Blood (2023) 142 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2023-185597

Published: 2023

Journal Articles

Spatial Technologies Reveal the Immune Landscape of Pediatric Acute Myeloid Leukemia

Joost B. Koedijk, Inge Van Der Werf, Marijn A. Vermeulen, Alicia Perzolli, Marta F. Fiocco, Hester A. de Groot-Kruseman, Rubina Moeniralam, Kristina B. Christensen, Henrik Hasle, Stefan Nierkens, Mirjam E. Belderbos, Michel C. Zwaan, Olaf Heidenreich

Blood (2023) 142 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2023-177932

Published: 2023

Journal Articles

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Martina Pigazzi, Claudia Tregnago, Rhonda E Ries, Maddalena Benetton, Todd A. Alonzo, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils Von Neuhoff, Henrik Hasle, Dirk Reinhardt, Franco Locatelli, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 840.

https://doi.org/10.1182/blood-2023-181872

Published: 2023

Journal Articles

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Sarah Elitzur, Ruth Shiloh, Jan Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Stephane Ducassou, Nizar Mahlaoui, Marion Strullu, Thomas Lehrnbecher, Kjeld Schmiegelow, Oussama Abla, Liliia Anderzhanova, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Francesco Ceppi, Nicole Bodmer, Triantafyllia Brozou, Luciano Dalla-Pozza, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Sarah K. Tasian, Thai Hoa Tran, Marek Ussowicz, Jose Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Ronit Nirel, Veronique Minard-Colin, Andishe Attarbaschi, Arndt Borkhardt

Blood (2023) 142 (Supplement 1): 520.

https://doi.org/10.1182/blood-2023-179333

Published: 2023

Journal Articles

Heterogeneous Gene Fusion Transcripts Found in t(7;12)(q36;p13) Acute Myeloid Leukemia but with Similar Gene Expression Profile

Anders Östlund, Anna Staffas, Ulrika Norén-Nyström, Henrik Hasle, Linda Fogelstrand, Jonas Abrahamsson, Lars Palmqvist

Blood (2023) 142 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2023-179814

Published: 2023

Journal Articles

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Blood (2023) 142 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2023-181792

Published: 2023

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

Blood (2022) 140 (Supplement 1): 1355–1356.

https://doi.org/10.1182/blood-2022-159002

Published: 2022

Journal Articles

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

Blood (2022) 140 (Supplement 1): 3403–3404.

https://doi.org/10.1182/blood-2022-156731

Published: 2022

Journal Articles

Association between Fc-Gamma Receptor Polymorphisms and Autoimmune Neutropenia in Early Childhood in Danish Patients

Kirstine Kløve-Mogensen, Rudi Steffensen, Tania Nicole Masmas, Petter Hoglund, Andreas Glenthøj, Thure Haunstrup, Paul Ratcliffe, Henrik Hasle, Kaspar Rene Nielsen

Blood (2022) 140 (Supplement 1): 5485–5486.

https://doi.org/10.1182/blood-2022-169621

Published: 2022

Journal Articles

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Henrik Hasle, Ronald M. Kline, Eigil Kjeldsen, Nik F. Nik-Abdul-Rashid, Deepa Bhojwani, Jeffrey M. Verboon, Stephanie P. DiTroia, Katherine R. Chao, Klas Raaschou-Jensen, Josefine Palle, C. Michel Zwaan, Charlotte Guldborg Nyvold, Vijay G. Sankaran, Alan B. Cantor

Blood (2022) 139 (21): 3159–3165.

https://doi.org/10.1182/blood.2021011463

Published: 2022

Includes: Supplemental data

Journal Articles

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Blood (2021) 138 (23): 2441–2445.

https://doi.org/10.1182/blood.2021012781

Published: 2021

Includes: Supplemental data

Journal Articles

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Blood (2021) 138 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2021-153346

Published: 2021

Journal Articles

Patient-Tailored Measurable Residual Disease Monitoring in Peripheral Blood Using Deep Sequencing and Droplet Digital PCR for Early Detection of Relapse in Childhood Acute Myeloid Leukemia: A NOPHO-DBH Collaborative Study

Anne-Sofie Skou, Kristian Løvvik Juul-Dam, Erik Delsing Malmberg, Anna Rehammar, Anastasia Soboli, Azadeh Anbarlou, Erik Kristiansson, Jonas Abrahamsson, Bernward Zeller, Kirsi Jahnukainen, Edwin Sonneveld, Birgitte Lausen, Anni Aggerholm, Hans Beier Ommen, Henrik Hasle, Linda Fogelstrand

Blood (2021) 138 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2021-153411

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Blood (2021) 138 (Supplement 1): 2360.

https://doi.org/10.1182/blood-2021-148041

Published: 2021

Journal Articles

NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136294

Published: 2020

NARROW

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012

Early Peripheral Blood Blast Clearance As a Prognostic Marker for Early Treatment Response in Pediatric Acute Myeloid Leukemia

Spatial Technologies Reveal the Immune Landscape of Pediatric Acute Myeloid Leukemia

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Heterogeneous Gene Fusion Transcripts Found in t(7;12)(q36;p13) Acute Myeloid Leukemia but with Similar Gene Expression Profile

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

Association between Fc-Gamma Receptor Polymorphisms and Autoimmune Neutropenia in Early Childhood in Danish Patients

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Patient-Tailored Measurable Residual Disease Monitoring in Peripheral Blood Using Deep Sequencing and Droplet Digital PCR for Early Detection of Relapse in Childhood Acute Myeloid Leukemia: A NOPHO-DBH Collaborative Study

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only